qEV Publication Watch: Q1 2022

1. Astrocyte-specific EV protein associated with Alzheimer’s disease

Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer's disease brain. Jan 2022, Journal of Extracellular Vesicles. doi: 10.1002/jev2.12183

‍

2. RBC-EVs as vehicles for immunomodulatory, anti-cancer RNA  

Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. Jan 2022, Journal of Extracellular Vesicles. doi: 10.1002/jev2.12187

‍

3. Breast cancer surface markers in EVs from lymphatic fluid

Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer. Jan 2022, BMC Cancer. doi: 10.1186/s12885-021-08870-w

‍

4. The search continues for more specific and reliable small EV markers

Tissue differences in the exosomal/small extracellular vesicle proteome and their potential as indicators of altered tissue metabolism. Jan 2022, Cell Reports. doi: 10.1016/j.celrep.2021.110277

‍

5. Small EVs in the gut-immune axis

Gut Microbiota-Derived Small Extracellular Vesicles Endorse Memory-like Inflammatory Responses in Murine Neutrophils. Feb 2022, Biomedicines. doi: 10.3390/biomedicines10020442

‍

6. Melanoma-derived EVs, lymphatic remodelling and tumour immunity

Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes. Feb 2022, Journal of Extracellular Vesicles. doi: 10.1002/jev2.12197

‍

7. EVs harvested by qEVoriginal columns in GFP-tagging study

GFP-tagging of extracellular vesicles for rapid process development. Mar 2022, Biotechnology Journal. doi: 10.1002/biot.202100583

‍

8. Anti-tumor immune responses associated with EVs from triple negative breast cancer cells  

Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome. Mar 2022, PNAS. doi: 10.1073/pnas.2107394119

‍

9. A comparison of EVs in cancerous versus healthy pancreatic organoids

Proteomic analysis distinguishes extracellular vesicles produced by cancerous versus healthy pancreatic organoids. Mar 2022, Scientific Reports. doi: 10.1038/s41598-022-07451-6

‍

10. Mechanisms of tumour-derived EVs in T cell activation

The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. Mar 2022, Journal for Immunotherapy of Cancer. doi: 10.1136/jitc-2021-003264

‍

In case you missed it: qEV10 Gen 2 Column Joins the Gen 2 Range